Skip to main content

Mycophenolate mofetil substitution for cyclosporine‐dependent myasthenia gravis and nephrotoxicity

Buy Article:

$51.00 plus tax (Refund Policy)


Severe autoimmune myasthenia gravis is difficult to manage and may require immunosuppression with cyclosporine. However, cyclosporine dependency is associated with the risk of nephrotoxicity. Mycophenolate mofetil is a non‐nephrotoxic alternative which should be considered to rescue cyclosporine‐dependent, severe myasthenia gravis sufferers with renal impairment from progression to end‐stage renal failure. However, the evidence is limited and studies have not assessed the outcome of a direct substitution in these cyclosporine‐dependent patients. We study three such patients who successfully converted to mycophenolate mofetil, and briefly examine the evidence behind this option. We believe that total cyclosporine withdrawal is feasible, but strongly recommend overlapping mycophenolate mofetil treatment with cyclosporine.

Keywords: cyclosporine; myasthenia gravis; mycophenolate mofetil; nephrotoxicity

Document Type: Research Article


Affiliations: Neurology, Austin Health, Melbourne, Victoria, Australia

Publication date: January 1, 2007

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more